[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552364":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":85,"collaborators":89,"id":93,"slug":25,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":25,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DREAMLAND","EXPERIMENTAL","DREAMLAND is a self-administered, multicomponent mobile psychological intervention application for patients to be used during their hospitalization for intensive chemotherapy.",[13],"Behavioral: DREAMLAND",{"label":15,"type":16,"description":17,"interventionNames":18},"VITAL WELLNESS","ACTIVE_COMPARATOR","VITAL WELLNESS is a self-administered, multicomponent mobile application containing information on a range of physical health topics that guide patients through education about general wellness, nutrition, exercise, and cancer prevention.",[19],"Behavioral: VITAL WELLNESS",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BEHAVIORAL","Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Areej El-Jawahri, MD","CONTACT","617-724-4000","ael-jawahri@mgb.org",{"name":36,"role":32,"phone":25,"phoneExt":25,"email":37},"Upeka Samarakoon, PhD","ssamarakoon@mgh.harvard.edu",[39,56,71],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Massachusetts General Hospital (MGH)","RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-71.05977,42.35843,{"lat":51,"lon":50},[54,55],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":36,"role":32,"phone":25,"phoneExt":25,"email":37},{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":45,"countryCode":46,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Duke University","NOT_YET_RECRUITING","Durham","North Carolina","27710",{"type":48,"coordinates":63},[64,65],-78.89862,35.99403,{"lat":65,"lon":64},[68],{"name":69,"role":32,"phone":25,"phoneExt":25,"email":70},"Thomas W LeBlanc, MD","thomas.leblanc@duke.edu",{"facility":72,"status":58,"city":73,"state":74,"zip":75,"country":45,"countryCode":46,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Fred Hutchinson Cancer Research Center (FHCRC)","Seattle","Washington","98109",{"type":48,"coordinates":77},[78,79],-122.33207,47.60621,{"lat":79,"lon":78},[82],{"name":83,"role":32,"phone":25,"phoneExt":25,"email":84},"Mohamed Sorror, MD","sorror@fredhutch.org",{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","El-Jawahri, Areej,M.D.","Associate Professor of Medicine",[90],{"name":91,"class":92},"National Cancer Institute (NCI)","NIH","100552364",false,"NCT06472128","Novel Digital Application for Patients With Acute Leukemia","Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia","NAVIGATE","Inclusion Criteria:\n\n* Hospitalized patients (age \\> 18 years) with a diagnosis of AML.\n* Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +\u002F- additional agents or modification of this regimen on a clinical trial.\n* Ability to comprehend and speak English as the digital apps are only available in English\n\nNote: Patients newly diagnosed as well as those with relapsed\u002Frefractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of acute promyelocytic leukemia\n* Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.","ALL","18 Years","120 Years",{"count":104,"type":105},200,"ESTIMATED","INTERVENTIONAL",[108],"NA","This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.",[111,112,113],"Relapsed Adult Acute Myeloid Leukemia","Primary Refractory Acute Myeloid Leukemia","High Risk Acute Myeloid Leukemia","2025-11-06",{"date":116,"type":117},"2025-11-10","ACTUAL",{"date":119,"type":117},"2024-10-21",{"date":121,"type":105},"2030-04-30",{"name":5,"class":6},3]